AllianceBernstein’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-1,343,480
| Closed | -$20.1M | – | 3303 |
|
|
2022
Q4 | $20.1M | Buy |
1,343,480
+1,218,830
| +978% | +$16.9M | 0.01% | 829 |
|
|
2022
Q3 | $1.03M | Buy |
+124,650
| New | +$957K | ﹤0.01% | 2275 |
|
|
2021
Q2 | – | Sell |
-25,000
| Closed | -$183K | – | 3543 |
|
|
2021
Q1 | $183K | Hold |
25,000
| – | – | ﹤0.01% | 3080 |
|
|
2020
Q4 | $144K | Hold |
25,000
| – | – | ﹤0.01% | 3060 |
|
|
2020
Q3 | $149K | Hold |
25,000
| – | – | ﹤0.01% | 3010 |
|
|
2020
Q2 | $129K | Buy |
+25,000
| New | +$158K | ﹤0.01% | 3074 |
|
|
2019
Q2 | – | Sell |
-6,580
| Closed | -$54K | – | 3222 |
|
|
2019
Q1 | $54K | Sell |
6,580
-980
| -13% | -$10.1K | ﹤0.01% | 3081 |
|
|
2018
Q4 | $121K | Buy |
7,560
+2,770
| +58% | +$60.9K | ﹤0.01% | 2974 |
|
|
2018
Q3 | $159K | Buy |
4,790
+2,150
| +81% | +$55.3K | ﹤0.01% | 3027 |
|
|
2018
Q2 | $60K | Buy |
+2,640
| New | +$62.6K | ﹤0.01% | 3086 |
|
|
2014
Q2 | – | Sell |
-5,526
| Closed | -$83K | – | 3723 |
|
|
2014
Q1 | $83K | Sell |
5,526
-947
| -15% | -$17K | ﹤0.01% | 3021 |
|
|
2013
Q4 | $119K | Sell |
6,473
-1,281
| -17% | -$25.7K | ﹤0.01% | 2902 |
|
|
2013
Q3 | $161K | Sell |
7,754
-325
| -4% | -$7.44K | ﹤0.01% | 2904 |
|
|
2013
Q2 | $202K | Buy |
+8,079
| New | +$345K | ﹤0.01% | 2843 |
|
AllianceBernstein's AVEO Position: Q1 2023 in Review
AllianceBernstein sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 1,343,480 shares — an estimated $20.1M sold.
AllianceBernstein first reported a position in AVEO in Q2 2013 and held it in 14 quarters. The position peaked at $20.1M in Q4 2022. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.
- AllianceBernstein reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- AllianceBernstein sold 1,343,480 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $20.1M.
- AllianceBernstein first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 14 quarters.
- AllianceBernstein's AVEO Pharmaceuticals, Inc. position peaked at $20.1M in Q4 2022.
- 0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.
Based on AllianceBernstein's 13F filing for Q1 2023, filed 15 May 2023.